Modeling Patient-Informed Liver Contrast Perfusion in Contrast-enhanced Computed Tomography.

OBJECTIVE: To determine the correlation between patient attributes and contrast enhancement in liver parenchyma and demonstrate the potential for patient-informed prediction and optimization of contrast enhancement in liver imaging. METHODS: The study included 418 chest/abdomen/pelvis computed tomography scans, with 75% to 25% training-testing split. Two regression models were built to predict liver parenchyma contrast enhancement over time: first model (model A) utilized patient attributes (height, weight, sex, age, bolus volume, injection rate, scan times, body mass index, lean body mass) and bolus-tracking data. A second model (model B) only used the patient attributes. Pearson coefficient was used to assess predictive accuracy. RESULTS: Weight- and height-related features were found to be statistically significant predictors (P < 0.05), weight being the strongest. Of the 2 models, model A (r = 0.75) showed greater accuracy than model B (r = 0.42). CONCLUSIONS: Patient attributes can be used to build prediction model for liver parenchyma contrast enhancement. The model can have utility in optimization and improved consistency in contrast-enhanced liver imaging.

A patient-informed approach to predict iodinated-contrast media enhancement in the liver.

OBJECTIVE: To devise a patient-informed time series model that predicts liver contrast enhancement, by integrating clinical data and pharmacokinetics models, and to assess its feasibility to improve enhancement consistency in contrast-enhanced liver CT scans. METHODS: The study included 1577 Chest/Abdomen/Pelvis CT scans, with 70-30% training/validation-testing split. A Gaussian function was used to approximate the early arterial, late arterial, and the portal venous phases of the contrast perfusion curve of each patient using their respective bolus tracking and diagnostic scan data. Machine learning models were built to predict the Gaussian parameters of each patient using the patient attributes (weight, height, age, sex, BMI). Pearson's coefficient, mean absolute error, and root mean squared error were used to assess the prediction accuracy. RESULTS: The integration of the pharmacokinetics model with a two-layered neural network achieved the highest prediction accuracy on the test data (R2 = 0.61), significantly exceeding the performance of the pharmacokinetics model alone (R2 = 0.11). Applying the model demonstrated that adjusting the contrast administration directed by the model may reduce clinical enhancement inconsistency by up to 40 %. CONCLUSIONS: A new model using a Gaussian function and supervised machine learning can be used to build liver parenchyma contrast enhancement prediction model. The model can have utility in clinical settings to optimize and improve consistency in contrast-enhanced liver imaging.